SCHEMBL5894567

SCHEMBL5894567

OC(c1ccccc1)n1cccn1

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.51
CYP19A1 P11511 7/20 0.41
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.37
HMOX2 P30519 1/20 0.35
EGLN1 Q9GZT9 2/20 0.35
LMNA P02545 3/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
SLC6A3 Q01959 2/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21547790 0.81 TSHR (0.49) TSHRCYP19A1KDM4ESMN1; SMN2HMOX2
SCHEMBL5865713 0.79 CYP19A1 (0.57) TSHRCYP19A1KDM4EEGLN1SLC6A2
SCHEMBL3996750 0.78 CYP19A1 (0.46) TSHRCYP19A1KDM4ESLC6A2SLC6A4
SCHEMBL23343730 0.76 TSHR (0.43) TSHRCYP19A1KDM4EHMOX2EGLN1
SCHEMBL28827501 0.76 TSHR (0.43) TSHRCYP19A1KDM4ESMN1; SMN2SLC6A2
SCHEMBL730575 0.76 TSHR (0.43) TSHRCYP19A1KDM4EHMOX2EGLN1
SCHEMBL15174490 0.76 CYP2D6 (0.45) TSHRCYP19A1KDM4ELMNA
SCHEMBL22369257 0.76 CYP2D6 (0.45) TSHRCYP19A1KDM4ELMNA
SCHEMBL5134511 0.76 LMNA (0.46) TSHRCYP19A1KDM4EHMOX2EGLN1
SCHEMBL11499232 0.73 TSHR (0.41) TSHRCYP19A1HMOX2EGLN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1317966-A Use of derivatives of aryl (or heteroaryl) pyrrolylcarbinol for the manufacture of a medicament for the treatment of diseases mediated by an excess of substance P ESTEVE LABOR DR (ES) 2001-10-17 CN claimed
US-20160347716-A1 Water-Soluble Pyrazole Derivatives as Corrosion Inhibitors ECOLAB USA INC. (US) 2016-12-01 US disclosed
WO-2016191677-A1 WATER-SOLUBLE PYRAZOLE DERIVATIVES AS CORROSION INHIBITORS ECOLAB USA INC. (US) 2016-12-01 WO disclosed
US-7129361-B2 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-10-31 US disclosed
EP-1072266-B1 THIENYLAZOLYLALCOXYETHANAMINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS ESTEVE LABOR DR (ES) 2005-08-24 EP disclosed
US-20040162324-A1 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. 2004-08-19 US disclosed
US-20020188017-A1 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. 2002-12-12 US disclosed
US-6410582-B1 ANALGESICS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2002-06-25 US disclosed
EP-1072266-A1 THIENYLAZOLYLALCOXYETHANAMINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347716-A1 Water-Soluble Pyrazole Derivatives as Corrosion Inhibitors BLVRB, CAT, PPOX TSHR 1860/4885CYP19A1 412/4885KDM4E 4637/4885
US-20020188017-A1 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments HNMT, HRH4, PNMT TSHR 351/4885CYP19A1 2812/4885KDM4E 1013/4885
US-20040162324-A1 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments HNMT, HRH4, PNMT TSHR 351/4885CYP19A1 2812/4885KDM4E 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.